The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
MagrathI., AddeM., ShadA.. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol.1996; 14(3): 925–934.
2.
WangE.S., StrausD.J., Teruya-FeldsteinJ.. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human-immunodeficiency virus-associated Burkitt lymphoma. Cancer.2003; 98(6): 1196–1205.
3.
MoletiM.L., TestiA.M., GionaF.. CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience. Leuk Lymphoma.2007; 48(3): 551–559.
4.
MeadG.M., SydesM.R., WalewskiJ.. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom lymphoma group LY06 study. Ann Oncol.2002; 13(8): 1264–1274.
5.
AddeM., ShadA., VenzonD.. Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphoma. Semin Oncol.1998; 25(2 Suppl 4): 33–39.
6.
MeadG.M., BarransS.L., QianW.. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt's lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood.2008; 112(6): 2248–2260.
7.
LacasceA., HowardO., FisherD.. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma.2004; 45(4): 761–767.
8.
DavidsonK.L., DevaneyM.B., TigheJ.E.. A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle lymphoma group study. Haematologica.2003; 88(12): 1366–1371.
9.
MontotoS., WilsonJ., ShawK.. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. AIDS.2010; 24(6): 851–856.
TrisselL., ZhangY., CohenM.The stability of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection. Hosp Pharm.2001; 36(7): 740–745.
12.
HeskethP.J., KrisM.G., GrunbergS.M.. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
13.
National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines – antiemesis. v.3.2009. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed April 25, 2010.
14.
KrisM.G., HeskethP.J., SomerfieldM.R.. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: update 2006. J Clin Oncol.2006; 24(18): 2932–2947.
15.
Multinational Association for Supportive Care in Cancer.Antiemetic guidelines. March 2008. Multinational Association for Supportive Care in Cancer Web site. Accessed April 30, 2010.
16.
WarrD.G., HeskethP.J., GrallaR.J.. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol.2005; 23(12): 2822–2830.
17.
GelingO., EichlerH.G.Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
18.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
19.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
20.
de WitR., de BoerA.C., vd LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 19;85(8):1099–1101.
21.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
22.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
23.
MartinM.The severity and pattern of emesis following different cytotoxic agents. Oncology.1996; 53(suppl 1): 26–31.
24.
BeckT.M.The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron. Anticancer Drugs.1995; 6(2): 237–242.
25.
StillwellT.J., BensonR.C.Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer.1988; 61(3): 451–457.
26.
Methotrexate [package insert].Bedford, OH: Ben Venue Laboratories;; 2005.
ZanottiK.M., MarkhamM.Prevention and management of antineoplastic-induced Hypersensitivity reactions. Drug Safety.2001; 24(10): 767–779.
29.
SmithT.J., KhatcheressianJ., LymanG.H.. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
30.
NCCN Clinical Practice Guidelines in Oncology – myeloid growth factors. v.1.2009. National Comprehensive Cancer Network Web site. http://www.nccn.org. Accessed April 25, 2010.
31.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
32.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?. Plast Reconstr Surgery.1985; 75(3): 397–402.
33.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
AronoffG.R., BennettW.M., BernsJ.S.. Drug Prescribing in Renal Failure.5th ed.Philadelphia: American College of Physicians; 2007.
37.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
38.
FloydJ., MirzaI., Sachs, PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33: 50–67.
39.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapy. Oncologist.2001; 6: 162–176.
